Lofexidine

(Lucemyra®)

Lucemyra®

Drug updated on 11/16/2023

Dosage FormTablet (oral; 0.18 mg)
Drug ClassCentral alpha-2 adrenergic agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Lucemyra (lofexidine) Prescribing Information.2020US Worldmeds LLC, Louisville KY

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
The ASAM national practice guideline for the treatment of opioid use disorder.2020American Society of Addiction Medicine